The EVI1 gene (3q26) codes for a transcription factor with important roles in normal hematopoiesis and leukemogenesis. High expression of EVI1 is a negative prognostic indicator of survival in acute myeloid leukemia (AML) irrespective of the presence of 3q26 rearrangements. However, the only known mechanisms that lead to EVI1 overexpression are 3q aberrations, and the MLL-ENL oncoprotein, which activates the transcription of EVI1 in hematopoietic stem cells. Our aim was to characterize the functional promoter region of EVI1, and to identify transcription factors involved in the regulation of this gene. Generation of seven truncated constructs and luciferase reporter assays allowed us to determine a 318-bp region as the minimal promoter region of EVI1. Sitedirected mutagenesis and chromatin immunoprecipitation (ChIP) assays identified RUNX1 and ELK1 as putative transcription factors of EVI1. Furthermore, knockdown of RUNX1 and ELK1 led to EVI1 downregulation, and their overexpression to upregulation of EVI1. Interestingly, in a series of patient samples with AML at diagnosis, we found a significant positive correlation between EVI1 and RUNX1 at protein level. Moreover, we identified one of the roles of RUNX1 in the activation of EVI1 during megakaryocytic differentiation. EVI1 knockdown significantly inhibited the expression of megakaryocytic markers after treating K562 cells with TPA, as happens when knocking down RUNX1. In conclusion, we define the minimal promoter region of EVI1 and demonstrate that RUNX1 and ELK1, two proteins with essential functions in hematopoiesis, regulate EVI1 in AML. Furthermore, our results show that one of the mechanisms by which RUNX1 regulates the transcription of EVI1 is by acetylation of the histone H3 on its promoter region. This study opens new directions to further understand the mechanisms of EVI1 overexpressing leukemias.
INTRODUCTION
The EVI1 gene (3q26) encodes a transcription factor that mediates essential functions in hematopoietic stem cells (HSC) and in leukemogenesis. EVI1 is indispensable for the proliferation and self-renewal of HSCs during embryogenesis and in the adult, 1, 2 and is downregulated upon differentiation. However, in megakaryocytic differentiation, the regulation of EVI1 should be different, as it is highly expressed in megakaryocytes. 3 Because of its distinctive biological and clinical features, acute myeloid leukemia (AML) patients with 3q21q26 aberrations and EVI1 rearranged have been included as a new entity in the 2008 World Health Organization classification of human myeloid neoplasms. 4 However, EVI1 overexpression is a prognostic indicator of poor survival irrespective of 3q26 rearrangements. [5] [6] [7] [8] EVI1 is part of a larger MDS1EVI1 complex locus (MECOM). The intergenic splicing between MDS1 and EVI1 leads to the nononcogenic protein MDS1EVI1, that contains 188 additional amino acids and has a PR domain (Supplementary Figures 1a and c) . 9 Moreover, EVI1 gives rise to several alternative 5 0 -end variants with the same translation start site, and due to alternative splicings, encodes several zinc-finger protein isoforms (Supplementary Figure 1) . 9, 10 The mechanism by which EVI1 operates in the transformation of hematopoietic cells is not well understood. It has been shown that EVI1 upregulates cell proliferation through the activation of AP1, and by repression of transforming growth factor beta (TGFb). 9 Moreover, high EVI1 blocks differentiation through its interaction with transcription factors essential in hematopoiesis such as GATA1, 11 PU.1 12 and RUNX1. 13 Despite the importance of EVI1 overexpression and its prognostic impact in AML, there are few data about the mechanisms involved in its regulation. As mentioned above, it is well known that 3q26 rearrangements lead to EVI1 overexpression. The most frequent aberrations are inv(3)(q21q26) and t(3;3)(q21;q26). In both cases, EVI1 overexpression seems to be forced by the enhancer of RPN1 (3q21); 10 although the high heterogeneity in the breakpoint locations suggests a complex mechanism.
14 Moreover, EVI1 is also deregulated in about 10% of patients with no 3q26 rearrangements. Notably, it has been recently described that the MLL-ENL oncoprotein activates EVI1 in HSC-derived MLL leukemic cells. 15 Therefore, further investigation is necessary to clarify how EVI1 is activated in other leukemias.
In this report, we investigate the putative promoter region of the EVI1 oncogene in order to investigate other mechanisms that lead to EVI1 overexpression in AML. We determine a minimal functional promoter region of EVI1 of 318 bp. Moreover, our functional experiments demonstrate that the transcription factors RUNX1 and ELK1 are involved in the transcriptional regulation of this gene, and that RUNX1 regulates EVI1 during megakaryocyte differentiation.
RESULTS
Identification and characterization of the EVI1 minimal promoter region. In order to characterize the minimal promoter region of EVI1, we analyzed 2134 bp 5 0 -upstream of the TSS (transcription start site) of EVI1-1C. Bioinformatics analysis showed a highly GC-rich region and no TATA or CAAT box. This region covers the putative proximal promoter regions of the alternative 5 0 -end variants EVI1-1A, -1B, -1C and -1D (Figure 1 ). Data obtained from bioinformatics predictions allowed us to generate serial 5 0 truncation constructs ( Figure 1 ). Constructs were cloned upstream of the luciferase reporter gene and transfected into different tissue derived cell lines: HEK293T, HEL and A549. Luciferase experiments suggested that the 2134-bp region analyzed displayed promoter activity ( Figure 2 ). Transfection of pGL3-1109 resulted in a decreased promoter activity. However, the promoter activity dropped more significantly when pGL3-1551 and pGL3-249 were transfected, reaching levels of pGL3basic, showing that the 318-bp region (pGL3-318) holds 450% of the full-length construct activity (Figure 2 ). Taken together, these results show the importance of the 318-bp region in the transcription of the human EVI1 gene. Functional characterization of the transcription factors involved in EVI1 regulation We next analyzed the 318-bp sequence using the MATCH (Wolfenbü ttel, Germany), TFSEARCH (Kyoto, Japan) and MatInspector (Munich, Germany) softwares, and found putative binding sites for several transcription factors (Figure 3a) . Site-directed mutagenesis allowed us to define the contribution of these hypothetical binding sites. Transfection of the mutated constructs in HEK293T and A549 showed a decrease in the reporter activity when five sites were mutated (MYB, GATA1(1 þ 2), REL/RELA/ELK1 and RUNX1) (Figure 3b ). RUNX1 and ELK1 regulate the transcription of EVI1 and bind to the minimal promoter region To study the importance of these putative transcription factors, we knocked down RUNX1, ELK1, GATA1, GATA2, MYB, REL and RELA. As our mail goal was to understand the regulation of EVI1 in AML, we selected for the analysis two myeloid cell lines with high EVI1 expression: HEL, with 3q rearrangements and the 318-bp region not disrupted; and F36-P, with no 3q aberrations.
14 RUNX1 and ELK1 knockdown separately and in combination, caused a significant reduction in EVI1 at protein and mRNA levels (EVI1-1A, -1B and -1D) in both cell lines (Figure 4 ; Supplementary  Figure 2 ). To corroborate these results, we transfected RUNX1 and ELK1 expression vectors in HEL and in HL-60, a cell line with no EVI1 protein and low levels of RUNX1 and ELK1 (Supplementary Table 1 ). RUNX1 overexpression increased EVI1 at both protein and mRNA levels in HEL, and mRNA levels in HL-60 (Figures 5a-c) . ELK1 overexpression increased EVI1 mRNA expression level in HL-60 (Supplementary Figures 3a-c) . The expression levels of EVI1 are very low in HL-60; therefore, we measured EVI1 expression with primers that amplified exons [11] [12] , covering all EVI1 transcripts (Figure 5c; Supplementary Figure 3c) .
To determine whether RUNX1 and ELK1 can transactivate the EVI1 promoter in myeloid cells, HEL cells were cotransfected with the pGL3-318 plasmid and RUNX1 or ELK1 expressing vector. Luciferase assays showed that RUNX1 and ELK1 activated the reporter plasmid; however, the ability of RUNX1 or ELK1 to activate the promoter of EVI1 disappeared when either the RUNX1 or ELK1-binding sites were mutated (Figure 5d ; Supplementary  Figure 3d ). Taken together, these observations suggest that RUNX1 and ELK1 could be direct transactivators of EVI1.
To further investigate RUNX1 or ELK1 recruitment to EVI1 in the 318-bp region, we performed ChIP assay followed by quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR). Binding of RUNX1 and ELK1 was demonstrated in HEL. As initial characterization of the EVI1 promoter was carried out in HEK293T, binding of RUNX1 was demonstrated in these cells ( Figure 6a ). As indicated above, we found no differences in EVI1 after knocking down or overexpressing GATA1 (data not shown); however, since GATA1 interacts with EVI1 at protein level, 11 and together with the GATA1 ChIPseq results reported, 16 we also performed ChIP against GATA1. We observed that GATA1 bound to the promoter of EVI1 (Figure 6a ). These results indicate that RUNX1, ELK1 and GATA1 bind to the EVI1 promoter in vivo. Immunoprecipitation experiments with anti-ELK1 showed that RUNX1 and GATA1 co-immunoprecipitated with ELK1. Moreover, we confirmed the physical interaction between RUNX1 and GATA1 ( Figure 6b ). The sequence between pGL3-1799 and pGL3-1109 also seemed important, as deletion of this region led to loss of half the activity (Figure 2 ). Since this region has predicted binding sites for RUNX1, ELK1 and GATA1, we Characterization of the promoter of EVI1 M Maicas et al performed ChIP assays; however, we found no binding of these proteins to this region (data not shown), suggesting that other transcription factors are also involved in the regulation of EVI1.
The Kasumi-1 cell line contains the t(8;21) that codifies the RUNX1-RUNX1T1 (AML1-ETO) fusion protein, which has a dominant negative effect on RUNX1. 17 To determine whether the presence of endogenous RUNX1-RUNX1T1 prevents the activation of EVI1, the construct pGL3-318, with or without the RUNX1-binding site mutated, was transfected into Kasumi-1 and HEL (RUNX1 wild type (WT)). Transfection of the construct with the RUNX1-binding site mutated in HEL showed a decrease in luciferase activity; however, there was a slight increase in Kasumi-1. This would suggest that RUNX1 binds to the 318-bp promoter region activating EVI1 expression, while the fusion protein, acting in a dominant negative manner on RUNX1, could be repressing it ( Figure 7 ).
In addition, we corroborated in HEL the results obtained in HEK293T and A549 cell lines. Transfection of the 318-bp region with RUNX1 or ELK1-binding sites mutated decreased the luciferase activity; however, transfection of the construct with both binding sites mutated had no additive effect (Figure 7 ), suggesting that they could be involved in a protein complex rather than acting separately.
RUNX1 is involved in the acetylation of the Histone 3 in the EVI1 promoter. RUNX1 associates with coactivators such as CBP/p300, and is involved in chromatin remodeling complexes. 18 Besides, we have previously shown that chromatin modifications in the promoter region of EVI1 are involved in its regulation.
14 This prompted us to study the acetylation status of the EVI1 promoter region after overexpressing RUNX1. Quantification of chromatin immunoprecipitated with anti-acetyl-histone-H3 and anti-acetyl-histone-H4 showed an increase in the active mark of acetylation of the histone H3 after the overexpression of RUNX1 (Figure 5e ). These data suggest that RUNX1 activates EVI1 transcription through the acetylation of its promoter region.
EVI1 expression correlated with RUNX1 expression in AML patients
To analyze the clinical relevance of these findings, we investigated the expression of EVI1, RUNX1 and ELK1 in 43 samples of patients with AML. We observed a significant positive correlation between EVI1 and either RUNX1 or ELK1 when using primers that recognize all the EVI1 transcripts, and when we specifically analyzed transcripts EVI1-1A and EVI1-1B in the 41 AML samples we had material left (Supplementary Table 2 ; Supplementary Figure 4) . We also found a significant positive correlation between RUNX1 and ELK1 (R ¼ 0.774; Po0.001) in our series. Interestingly, the nine patients with 3q rearrangements expressed higher levels of RUNX1, ELK1 and EVI1 (in two cases we had material left, we confirmed that the 318-bp region was not disrupted). We analyzed EVI1, RUNX1 and ELK1 proteins in 16 cases with AML. Western blot showed increased levels of the two longer isoforms of RUNX1 in cases with EVI1 overexpression (Figure 8 ; Supplementary Table 4) . We detected ELK1 protein in all cases analyzed. Taken together, these results show that RUNX1 could regulate EVI1 expression in human AML.
The fact that RUNX1 mutations are common in AML 19 prompted us to analyze their prevalence in our series of patients. Mutation analysis of exons 3-6 of RUNX1 in 27 cases we had material left, and of exons 3-8 in the 15 cases with protein data, showed four heterozygous mutations in the RUNT domain, and two silent mutations in exon 8 (Supplementary Table 3 ).
EVI1 is a downstream target of RUNX1 in megakaryocytic differentiation RUNX1 expression is upregulated in K562 cell line after the induction of megakaryocytic differentiation by TPA, 20 and EVI1 is expressed during megakaryocytic differentiation. 3 To investigate whether RUNX1 could regulate EVI1 in this process; we treated K562 cells with TPA. We confirmed an increase in RUNX1 and in the megakaryocytic markers ITGA2B/ITGB3. 21 Moreover, we also observed an increase of both EVI1 and ELK1 (Figures 9a and b) . RUNX1 knock down resulted in marked decrease of the TPA induction of the megakaryocytic markers, 21 and in a decrease in EVI1. Furthermore, EVI1 knock down also led to a reduction of the megakaryocytic markers (Figures 9b and c) . ChIP assay confirmed a higher occupancy of RUNX1 in the promoter region of EVI1 after TPA treatment (Figure 9d ). Knocking down of ELK1 produced no effects either in the differentiation markers or in EVI1, indicating that ELK1 is dispensable during this process (Figures 9b and c) . Besides, ELK1 and GATA1 bound equally to this region before and after the treatment (Figure 9d ). Altogether, these results suggest that one of the mechanisms by which RUNX1 exerts its role in megakaryocytic differentiation is through the regulation of EVI1.
There are no mutations in the EVI1 promoter in AML We next investigated the presence of point mutation in the EVI1 promoter as a mechanism of its overexpression. To test this hypothesis, we analyzed a region of 1601 bp upstream of the region of the TSS of EVI1-1C in KU-812 and KYO-1 (EVI1 overexpression and no 3q aberrations), HEL (EVI1 overexpression and 3q aberrations), and OCI-AML2 (no EVI1 expression and 3q aberrations). We also analyzed 19 samples of AML patients with EVI1 overexpression and no 3q rearrangements and 5 normal controls. We found no mutations in these samples. Sequencing revealed four previously described SNPs that did not change or create transcription binding sites (Supplementary Figure 5) .
DISCUSSION
Several reports have demonstrated that EVI1 overexpression is associated with poor prognosis in AML, irrespective of the presence of 3q26 rearrangements; [5] [6] [7] [8] however, little is known about the normal or aberrant regulation of this gene at transcriptional level. This prompted us to analyze the transcriptional regulation of EVI1. In this study, we characterize for the first time a minimal promoter region of 318 bp in the human EVI1 gene, and we show that RUNX1 and ELK1 are directly involved in the activation of EVI1 at transcriptional level.
Bioinformatics analysis and luciferase assays of a region that includes the 5 0 -ends of all transcripts allowed us to identify that part of the necessary machinery for driving basal EVI1 expression is located in a 318-bp region, which holds 450% of the full-length construct activity, and has putative binding sites for several transcription factors (Figures 2 and 3) . Furthermore, our results in the human cell lines A549 and HEK293T showed that this functional promoter region is not restricted to AML. We have recently reported that methylation of the CpG island-1, and acetylation and methylation of the histones in the EVI1 promoter region could be involved in its regulation. 8 Interestingly, CpG island-1 is included in the 318-bp sequence determined in this study (Figure 1 ), underlining the importance of this region. In addition, bioinformatics analysis identified a RARE (retinoic acid response element) in this 318 bp region. Previously, Bingeman et al. 22 identified a functional RARE located in the 5 0 region of EVI1, which is included in our 2134 bp region. We confirmed their results in the same cell line they used (NTERA-2) and in HEK293T; however, we found that this element in the 318-bp region was not functional (Supplementary Figure 6) .
Site-directed mutagenesis, knock down and overexpression experiments identified RUNX1 and ELK1 as putative transcriptional regulators of EVI1. After knocking down both transcription factors concomitantly, we did not observe a higher decrease, indicating that they should be involved in a protein complex rather than acting separately (Supplementary Figure 2) . As our main goal was to understand the regulation of EVI1 in AML, we performed these experiments in AML cell lines. Notably, F36-P, one of the cell lines used, overexpresses EVI1 and has no 3q rearrangements, 8 indicating that the transcriptional regulation of EVI1 through RUNX1 and ELK1 is independent of 3q rearrangements. In addition, our results showed that RUNX1 and ELK1 regulate several EVI1 transcripts (Figure 4) , supporting previous data that showed similar expression patterns of all transcripts in most tissues. 
Characterization of the promoter of EVI1 M Maicas et al
Quantification of EVI1, RUNX1 and ELK1 expression in 43 AML cases showed correlation between EVI1 and RUNX1 or ELK1. Interestingly, this analysis showed that patients with 3q rearrangements also expressed high levels of RUNX1 and ELK1, indicating that both mechanisms could be involved in the regulation of EVI1. Moreover, we found a positive correlation between the two longer isoforms of RUNX1 and EVI1 at protein level, confirming the clinical importance of these findings (Figure 8 ).
RUNX1 is a member of a family of transcription factors that plays essential roles in hematopoiesis. 18 The transcription activity of RUNX1 depends on its ability to interact with other proteins. It is well known that RUNX1 is involved in chromatin remodeling complexes through its association with coactivators such as CBP/ p300. 18 Our results show that one of the mechanisms by which RUNX1 regulates the transcription of EVI1 is by acetylation of histone H3 in its promoter region (Figure 5e ). Interestingly, we have previously reported that cell lines overexpressing EVI1 have an enrichment of histone H3/H4 acetylation; 8 therefore, RUNX1
could be involved in the chromatin remodeling of the promoter of EVI1. Moreover, it is noteworthy that in the Kasumi-1 cell line with the RUNX1-RUNX1T1 fusion protein, the luciferase activity did not decrease after transfection of the 318-bp region with the RUNX1-site mutated, as happened in the RUNX1 WT HEL cell line ( Figure 7 ). This would indicate that RUNX1-RUNX1T1 could be binding to this site and preventing the activation of EVI1 by RUNX1, supporting previous studies that demonstrated that RUNX1-RUNX1T1 is unable to interact with proteins with HAT activity, and instead interacts with corepressors, including HDACs, 17 avoiding the transcriptional activation of the RUNX1 target genes.
RUNX1 also interacts with lineage-specific transcription factors whose DNA-binding consensus sites are located next to that of RUNX1 such as PU.1, c-MYB, ETS and GATA1. 18 As shown in Figure 3a , some of these transcription factors have hypothetical binding sites next to RUNX1 in the 318-bp, suggesting that they might cooperate in the regulation of EVI1. Transcriptional cooperation between RUNX1 and GATA1 in the activation of megakaryocytic promoters has been established by reporter assays, 24 and the two factors physically interact. 20 Our results show that RUNX1, ELK1 and GATA1 interact with each other, forming a regulatory protein complex that binds to the EVI1 promoter region (Figure 6 ), although GATA1 absence is not sufficient to cause changes in EVI1 levels.
Dysplasia of megakaryocytes is a clinical feature of patients with EVI1 overexpression. 10 In fact, EVI1 is involved in megakaryocytic differentiation. 3, 25 Using K562 cells, a well-characterized system for studying megakaryopoiesis, 21 we found that RUNX1 is involved in the regulation of EVI1 during megakaryocyte differentiation and that both proteins are necessary in this process ( Figure 9 ). Moreover, our results indicate that ELK1 and GATA1 might participate in this regulation, although ELK1 is dispensable in this mechanism. Goyama et al. 1, 21 described ITGA2B and ITGB3 as potential target genes of EVI1, supporting our results, and suggesting that both RUNX1 and EVI1 participate in the regulation of both differentiation markers.
It has been reported that EVI1 interacts with RUNX1 at protein level, modifying its ability to bind DNA and consequently, to regulate its target genes. 13 Our results suggest that RUNX1 and EVI1 could be regulating each other. RUNX1 would activate EVI1 transcription, and when highly expressed, EVI1 could bind to RUNX1 at protein level, inhibiting its activity as a transcription factor, acting in a negative feedback. As EVI1 is expressed in megakaryocytes, 3 we postulate that its abnormal upregulation could contribute to the dismegakaryopoiesis that patients with high EVI1 expression show, also due to the blockade of the expression of the RUNX1 target genes. Moreover, AML patients with overexpression of these transcription factors have poor prognosis. [5] [6] [7] [8] 18 Several mutations have been identified in RUNX1. 26 In a series of 43 patients, we found four mutations in the RUNT-homologydomain (Supplementary Table 3 ). There are no functional experiments with two of the mutations found (N109K and S67I), although N109K maps to a previously defined energetic hot spot at the heterodimerization interface with core binding factor (CBFb), suggesting a loss of function. 27, 28 Interestingly, we found a high positive correlation between RUNX1 and EVI1 expression at protein level in three patients with these mutations. Further studies are needed to determine the effect of RUNX1 mutations in the transcriptional regulation of EVI1.
29
Another major finding of this report is the evidence of the transcriptional regulation of EVI1 by ELK1, a member of the ETS family of transcription factors. 30 Interestingly, these members are classical activators that play a primary role in the formation of the initiation complex on minimal core promoters lacking the TATA sequence, such as EVI1; 31 however, there are few data concerning ELK1 and AML. 32 We show for the first time that ELK1 is Figure 6 . RUNX1, ELK1 and GATA1 associate with each other in the promoter region of EVI1. (a) ChIP assay performed in the HEL and HEK293T cell lines. qRT-PCR was performed on fragmented chromatin precipitated by Normal rabbit IgG (ELK1) or Normal goat IgG (RUNX1, GATA1), or the specific anti-RUNX1, anti-ELK1 or anti-GATA1 antibodies. The promoter region of GAPDH was used as a negative region, and cFOS or GATA2 promoter regions as positive controls for ELK1 or GATA1 binding, respectively. qRT-PCR results were calculated using the 2-DDCt method, and they are presented as the fold enrichment of chromatin DNA precipitated by the specific antibody versus chromatin DNA precipitated by normal IgG, as control. (b) Protein immunoprecipitation assay using anti-RUNX1, anti-ELK1 and anti-GATA1 or non-specific IgGs used as a control. Then, the immunoprecipitates were analyzed for the presence of RUNX1, ELK1 or GATA1.
upregulated during the megakaryocytic differentiation directed by TPA (Figure 9 ). It has been reported that TPA treatment in cells stably expressing ELK1, 33 and TPO treatment of UT-7 cells 34 that induce megakaryocytic differentiation, lead to ELK1 phosphorylation, inducing its activation; however, to our knowledge there are no data about its transcriptional upregulation by TPA. Moreover, we found that all cases analyzed expressed ELK1 at protein level. Since ELK1 is known to be activated through phosphorylation, 30 we hypothesize that ELK1 could regulate the expression of EVI1 as a consequence of its activation through different signals, and not by a higher expression.
Taken together, our results suggest that a transcriptional complex formed by RUNX1, ELK1 and GATA1 could establish different chromatin states in the EVI1 promoter, and that an aberrant regulation could be involved in the transformation of AML. Furthermore, the analysis of the expression of EVI1 at protein level in 16 patients with AML found a positive correlation with RUNX1, showing the clinical relevance of these findings. This study opens new directions to further understand the mechanisms of EVI1 overexpressing leukemias; however, more studies are needed to uncover the complex transcriptional regulation of EVI1.
MATERIALS AND METHODS

Cell lines and patient samples
Characteristics of the cell lines are summarized in Supplementary Table 1 . We analyzed bone marrow samples of 43 AML patients at diagnosis (Supplementary Table 5 ), and five normal donors. The study was carried out in accordance with the ethical guidelines of our institution. All samples were taken anonymously. K562 cells were stimulated with 40 nM phorbol-12-myristate-13-acetato (TPA).
Plasmid constructs and luciferase reporter assay Characterization of the promoter of EVI1 M Maicas et al Table 6 ), and cloned into KpnI-XhoI sites in promoterless luciferase reporter vector (pGL3-Basic) (Promega, Madison, WI, USA). Mutagenesis was performed by QuickChangeII Site-Directed Mutagenesis kit (Stratagene, Santa Clara, CA, USA) using pGL3-318 as template (Supplementary Table 6 ). Sequences were confirmed by sequencing. 7 Â 10 4 HEK293T or A549 were cotransfected using 1 ml Lipofectamine-2000 (Invitrogen, Carlsbad, CA, USA) with 500 ng of total DNA (390 ng pGL3-Basic as carrier DNA, 100 ng of the promoter construct and 10 ng of the internal standard pRL-SV40). 2 Â 10 6 HEL or Kasumi-1 cells were cotransfected using 15 ml Lipofectamine-2000 with 5 mg of the promoter construct, and 100 ng of pRL-SV40. To study the effect of overexpression of RUNX1 or ELK1 on the EVI1 promoter, 2 Â 10 6 HEL cells were transfected with 5 mg of WT or mutant 318 bp construct, with 500 ng RUNX1 expression plasmid (pFlagCMV2-AML1B (plasmid 12 504, Addgene, Cambridge, MA, USA) 35 ) or 2.5 mg ELK1 expression plasmid (pCDNA3-ELK1, kindly provided by Dr Hipskind) or the empty vectors in addition to 100 ng of pRL-SV40. To assess the ATRA responsiveness of the EVI1 promoter fragments, 7 Â 10 4 HEK293T or NTERA-2 cells were transfected. 22 Luciferase activity was measured after 40 h with Dual-Luciferase-Assay Kit (Promega). Firefly luciferase activities were normalized to renilla luciferase activities to adjust for variability in transfection efficiencies.
Bioinformatic analysis of the human promoter region of EVI1
As predictors of putative promoter regions within the 3000-bp before the TSS of the transcript EVI1-1C (NM_005241), we used Promoter 2.0 (http:// www.cbs.dtu.dk/services/Promoter/), ElDorado (http://www.genomatix.de/ cgi-bin/./eldorado/main.pl) PromoterScan (http://www-bimas.cit.nih.gov/ molbio/proscan/), and NNPP (http://www.fruitfly.org/seq_tools/promoter.html) softwares. Analysis of potential binding sites of transcription (RUNX1, GATA1) , or the specific anti-RUNX1, anti-ELK1 or anti-GATA1 antibodies. The promoter region of GAPDH was used as a negative region, and LMO2 or cFOS promoter regions as positive controls for RUNX1 and GATA1 or ELK1 binding, respectively. PCR results were calculated using the 2-DDCt method, and they are presented as the fold enrichment of chromatin DNA precipitated by the specific antibody versus chromatin DNA precipitated by normal IgG, as control (*Po0.05; **Po0.01; ***Po0.001).
factors within the 318-bp region was performed using MATCH (http:// www.gene-regulation.com/cgi-bin/pub/programs/match/bin/match.cgi) TFSEARCH (http://www.cbrc.jp/research/db/TFSEARCH.html) and MatInspector (http://www.genomatix.de/cgi-bin/./eldorado/main.pl) softwares.
Transient transfections
To knock down RUNX1 and ELK1 expression, 600 nM of the ON-TARGETplus SMARTpool siRNA-L-003926-00-0005, L-003885-00-0005 and EVI1 siRNA-D-006530-06, were transfected (Dharmacon, Laffayette, LA, USA). Block-It (Invitrogen) was used to assess non-specific gene silencing effects. HEL was nucleofected by Amaxa Nucleofector electroporation device (Amaxa Biosystems, Lonza, Walkersville, MD, USA). F36-P or K562 were transfected by electroporation with the Gene-Pulser-Xcell Electroporation System (Bio-Rad, Benicia, CA, USA) using 300 V and a capacitance of 1000 mF. Cell viability and transfection efficiency were 475%. Transfections were performed in two consecutive days to get a more stable inhibition. To overexpress RUNX1 and ELK1, HEL and HL-60 cells were transfected with the expression or empty vectors, using the Amaxa Nucleofector.
Western blot
Proteins from AML patients were extracted using the Trizol method (Invitrogen). Isolation of total proteins from cell lines was obtained with a 10 Â lysis buffer (Invitrogen), 200 mM Na 3 VO 4 and protease inhibitor mixture. Nuclear proteins were extracted with Nuclear Extraction Kit (Panomics, Santa Clara, CA, USA). Concentrations of protein extraction were determined by BCA Protein-Assay-Kit (Pierce, Rockford, IL, USA). Western blot analysis was carried out as previously described.
14 After incubation with anti-EVI1 antibody (Cell Signaling Technology, Danvers, MA, USA), anti-RUNX1 antibody (Active Motif, Carlsbad, CA, USA), anti-ELK1 antibody (Cell Signaling Technology), anti-b-actin antibody (Sigma, St Louis, MO, USA) or anti-lamin A/C antibody (Cell Signaling), detection was performed with horseradish peroxidase-coupled secondary antibodies (Sigma).
Quantitative real-time RT-PCR (qRT-PCR)
RNA was isolated using RNeasy-Mini-Kit (Qiagen, Valencia, CA, USA), and 2 mg were used for cDNA synthesis (SuperScripttII RNase-HRT; Invitrogen). qRT-PCR was performed with 20-50 ng of cDNA in the ABI-Prism-7500 (Applied Biosystems, Carlsbad, CA, USA) using specific assays for GAPDH, EVI1-1A, EVI1-1B and EVI1-1D as previously described. 14 Relative expression was normalized to GAPDH expression and calculated according to the 2-DDCt method. We measured total EVI1 with primers located in exons 11 and 12 (EVI1 11-12), and specific primers for ELK1, RUNX1, ITGA2B and ITGB3 (Supplementary Table 6 ; Supplementary Figure 1a) . Relative expression quantification was performed using the SYBR-green Master Mix (Applied Biosystems), and HPRT1 was used as endogenous control for normalization. EVI1 overexpression was defined as levels higher than the average of five bone marrow samples from healthy volunteers and three times the standard deviation.
ChIP assay
ChIP assays were performed using crosslinked isolated nuclei from 10 Â 10 6 of HEL, HEK293T and K562 cells. Chromatin was fragmented by sonication (Bioruptor, Diagenode, Belgium). To immunoprecipitate the protein-DNA complexes, protein-A/G or protein-G Plus agarose and 2 mg of each antibody were used; anti-RUNX1 antibody, anti-ELK1 antibody or anti-GATA1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Two controls were added, the total input and goat-IgG antibody (Santa Cruz Biotechnology) or anti-rabbit-IgG antibody (Cell Signaling). Amount of DNA was analyzed by qRT-PCR using the SYBR-Green assay (Supplementary Table 6 ). An unrelated genomic region of GAPDH gene was used as negative control (Diagenode, Denville, NJ, USA). Sequences of the primers of the promoter of cFOS were described previously. 36 To study the acetylation of H3 and H4 changes, HEL cells were transfected with RUNX1 expression vector. After 12 h, cells were subjected to ChIP, as previously described. 8 Protein immunoprecipitation HEL proteins were extracted with a lysis buffer (0.5% Triton X-100, 1 mM EDTA, 100 mM Na 3 VO 4 , 0.2 mM PMSF, 20 mM b-glicerolP and protease inhibitor mixtureI). In all, 1 mg of protein was incubated for 1-2 h at 4 1C with 10 mg of anti-ELK1, anti-GATA1 or anti-RUNX1 antibodies, crosslinked to protein G-Dynabeads following the manufacturer's instructions. After several washes, the immunoprecipitates were eluted in 0.1 M citrate and the elutes were subjected to western blot experiments.
Mutation analysis
Mutation analysis of the EVI1 promoter region (spanning from À1696 bp to À110 bp) and RUNX1 mutation screening were performed using primers listed in Supplementary Table 6 . All products were sequenced.
Statistical analysis
Statistical significance was estimated using parametric paired t-test and non-parametric Mann-Whitney two-tailed test or Wilcoxon-matched pairs test. A P-value of o0.05 was considered to be significant (*) or o0.01 or 0.001 very significant (** or ***). To evaluate the correlation analysis, Spearman's rank correlation coefficient was used when the values lacked a normal distribution. Statistical analysis was performed using the SPSS 15.0 statistical package (Chicago, IL, USA).
